Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The company is headquartered in Westlake Village, California.
| Revenue (TTM) | 8,000 |
| Gross Profit (TTM) | 8,000 |
| EBITDA | $-34.38M |
| Operating Margin | -432112.00% |
| Return on Equity | -127.30% |
| Return on Assets | -60.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.52 |
| Price-to-Book | 5.88 |
| Price-to-Sales (TTM) | 16590.95 |
| EV/Revenue | 13878.93 |
| EV/EBITDA | -327.19 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -95.30% |
| Shares Outstanding | $44.84M |
| Float | $36.11M |
| % Insiders | 13.12% |
| % Institutions | 30.67% |
Volatility is currently contracting
- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial -
-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Systemic lung cancer programs advancing with additional updates expected throughout 2026 -- -- $26.3 million in cash, cash equivalents, marketable securities and restricted cash as of March 31, 2026; expected to fund operations into 1Q27 -- WESTLAKE VILLAGE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2026 and provided general business updates.
